Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Malay K SannigrahiDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-0377-5771
Lovely RaghavDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-2017-5695
Dominick J RichDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-0540-3592
Travis P SchrankDepartment of Otorhinolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0002-8297-3329
Joseph A CalifanoDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA, United States.
John N LukensDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-7104-413X
Lova SunDivision of Hematology Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-5015-2964
Iain M MorganPhilips Institute for Oral Health Research and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.ORCID 0000-0002-4949-3032
Roger B CohenDivision of Hematology Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Alexander LinDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-1254-8324
Xinyi LiuDepartment of Pharmacology, University of Illinois at Chicago, Chicago, IL, United States.
Eric J BrownDepartment of Cancer Biology, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-6562-6512
Jianxin YouDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-9478-2159
Lisa MirabelloDivision of Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.ORCID 0000-0001-8485-0106
Sambit K MishraDivision of Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.ORCID 0000-0001-8319-0599
David ShimunovDepartment of Otolaryngology-Head and Neck Surgery, Stony Brook, NY, United States.ORCID 0000-0001-6138-4771
Robert M BrodyDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.
Alexander T PearsonDepartment of Medicine, University of Chicago Medical Center, Chicago, IL, United States.ORCID 0000-0003-2801-7456
Phyllis A GimottyD epartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-3850-9799
Ahmed DiabDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-6626-7013
Jalal B JalalyDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-6978-0242
Devraj BasuDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-0896-1490
Funding
Virus, Vector and Cell Culture CoreP01CA281867 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ERLE S. ROBERTSON · 2023 to 2026
$9.1M
Merkel cell polyomavirus infection, host response, and viral oncogenic mechanismR01CA187718 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Jianxin You · 2015 to 2026
$3.7M
Exploiting differences in HPV oncoprotein function among oropharyngeal cancers to personalize therapyR01DE034056 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI Devraj Basu · 2024 to 2026
$1.7M
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancerR01DE027185 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI BASU, DEVRAJ · 2018 to 2021
$1.5M
Targeting MCPyV oncogene transcription to suppress tumorigenesisR01CA284690 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Jianxin You · 2023 to 2026
$1.5M
Targeting the DNA Damage Response in HPV+ Head and Neck CancerR00DE030194 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI Ahmed Mohamed Diab · 2024 to 2026
$747k
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgeryUH2CA267502 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BASU, DEVRAJ · 2022 to 2023
$415k
A novel gene therapy approach targeting STING-silenced cold tumorsR21CA267803 · NCI · UNIVERSITY OF PENNSYLVANIA · PI YOU, JIANXIN · 2023 to 2024
$408k
Breakthrough Challenge FoundationNational Institute for Dental and Craniofacial ResearchNCI NIH HHS P01 CA281867NCI NIH HHS R01 CA187718NCI NIH HHS R01 CA284690NCI NIH HHS R21 CA267803NCI NIH HHS UH2 CA267502NIDCR NIH HHS R00 DE030194NIDCR NIH HHS R01 DE027185NIDCR NIH HHS R01 DE034056NIH HHS R00DE030194NIH HHS R01DE027185NIH HHS R01DE034056NIH HHS R21CA267803NIH HHS UH2CA267502Penn Synergy ProgramStephen and Susan Kelly Family Fund for Head and Neck CancersWilliam and Greta Lydecker Fund
6 · The paper itself
Abstract
backgroundLimited understanding of the biology predisposing certain human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) to relapse impedes therapeutic personalization. We aimed to identify molecular traits that distinguish recurrence-prone tumors.
methodsFifty HPV+ OPSCCs that later recurred (cases) and 50 nonrecurrent controls matched for stage, therapy, and smoking history were RNA-sequenced. Groups were compared by gene set enrichment analysis, and select differences were validated by immunohistochemistry. Features discriminating groups were scored in each tumor using gene set variation analysis, and scores were evaluated for recurrence prediction ability.
resultsCases downregulated pathways linked to antitumor immunity (FDR-adjusted P < .05) and contained fewer tumor-infiltrating lymphocytes (P < .001), including cytotoxic T-cells (P = .005). Cases also upregulated pathways related to cell division and other aspects of tumor progression. Upregulated and downregulated pathways were respectively used to define a tumor progression score (TPS) and immune suppression score (ISS) for each tumor. Correlation between TPS and ISS (r = .603, P < .001) was potentially explained by observed upregulation of DNA repair pathways in cases, which might enhance their progression directly and by limiting cytosolic DNA-induced inflammation. Accordingly, cases contained fewer double-strand breaks based on staining for phospho-RPA32 (P = .006) and γ-H2AX (P = .005) and downregulated the cytosolic DNA sensing pathway. A combined score derived from TPS and ISS optimized recurrence prediction and stratified survival in a manner generalizable to 3 external cohorts.
conclusionsWe describe a potential link in HPV+ OPSCCs between reduced DNA damage and other tumor-intrinsic and immune-related contributors to recurrence risk, opening opportunities to detect and target this high-risk biology.
Indexed as
Neoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckAdultAgedBiomarkers, TumorCase-Control StudiesFemaleHuman Papillomavirus VirusesHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPapillomaviridaeTreatment FailureBiomarkers, Tumor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. · full record | Socratic